Absci Enters into a Collaboration Agreement with AstraZeneca to Discover AI-Driven Oncology Treatment
Shots:
- The collaboration was signed to synergistically combine Absci's Integrated Drug Creation platform with AstraZeneca's expertise in oncology to discover a potential new cancer treatment candidate
- Under the terms of the agreement, Absci will receive an upfront payment, R&D funding & milestone payments all aggregating to a total of $247M plus royalties on product sales whereas AstraZeneca will leverage Absci's AI platform to discover products for an undisclosed oncology indication
- The Integrated Drug Creation platform from Absci utilizes scalable wet-lab technologies and generative AI to accelerate drug discovery by completing data collection, AI design, and wet-lab validation within 6wks.
Ref: Absci | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
